Drug updated on 5/30/2024
Dosage Form | Injection (subcutaneous; 94.5 mg/0.5 mL) |
Drug Class | HAO1-directed small interfering ribonucleic acid |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.
Latest News
Summary
- Lumasiran (Oxlumo) is indicated for the treatment of primary hyperoxaluria type 1 (PH1), a condition it treats by lowering urinary oxalate levels in both pediatric and adult patients.
- Four studies from randomized controlled trials were reviewed to gather information about this drug's safety, effectiveness, and considerations for different populations and subgroups.
- In infants and children under six years old, lumasiran was found to be effective in reducing spot urinary oxalate: creatinine ratio by 72% at six months. This effect was maintained through month twelve with an acceptable safety profile; the most common adverse events being mild injection-site reactions.
- For PH1 patients of all ages with advanced kidney disease including those undergoing hemodialysis, lumasiran showed substantial reductions in plasma oxalate levels while maintaining an acceptable safety profile irrespective of the severity of kidney function impairment.
- A double-blind phase three trial involving patients aged six or older demonstrated that lumasiran resulted in a significant reduction - 65.4% - in 24-hour urinary oxalate excretion compared to placebo. It also helped many treated patients achieve urinary oxalate excretion levels no higher than 1.5 times the upper limit of the normal range, indicating its efficacy against progressive kidney failure caused by PH1.
- The studies underline broad applicability across different patient subgroups including infants/young children as well as those with advanced kidney disease on hemodialysis; consistently showing acceptable safety profiles marked mostly by mild transient injection-site reactions, which positions Lumasiran as a significant therapeutic advancement for treating PH1 across various demographics/disease severities, pending comparisons based strictly on broader clinical data.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Oxlumo (lumasiran) Prescribing Information. | 2023 | Alnylam Pharmaceuticals, Inc., Cambridge, MA |
Randomized Controlled Trials
Document Title | Sex Distribution | Year | Source |
---|---|---|---|
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial. | 18Subjects F: 56% M: 44% | 2023 | Pediatric Nephrology |
Lumasiran for advanced primary hyperoxaluria type 1: Phase 3 ILLUMINATE-C trial. | 21Subjects F: 43% M: 57% | 2023 | American Journal of Kidney Diseases |
Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children. | 18Subjects F: 56% M: 44% | 2022 | Genetics in Medicine |
Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. | 39Subjects F: 33% M: 67% | 2021 | The New England Journal of Medicine |
Sex Distribution:
F:56%
M:44%
18Subjects
Year:
2023
Source:Pediatric Nephrology
Sex Distribution:
F:43%
M:57%
21Subjects
Year:
2023
Source:American Journal of Kidney Diseases
Document Title
Sex Distribution:
F:56%
M:44%
18Subjects
Year:
2022
Source:Genetics in Medicine
Sex Distribution:
F:33%
M:67%
39Subjects
Year:
2021
Source:The New England Journal of Medicine
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. | 2023 | Nature Reviews Nephrology |